Gynomax® XL Vaginal Ovule and Treatment of Common Vaginal Infections
Makaleler > Tam Makale · 2022
Yazarlar: Rujittika MUNGMUNPUNTIPANTIP, Viroj WIWANITKIT
Journal of Clinical Obstetrics & Gynecology, Uluslararası, Scopus, 2022, cilt 32, ss 37-37
Özet
We would like to discuss on the publication "The Efficacy and Safety of Gynomax ® XL Vaginal Ovule in the Treatment of Common Vaginal Infections: A Single-arm Clinical Trial." 1 Tavmergen et al. mentioned that "Gynomax ® XL vaginal ovules administered once daily for three consecutive days provide effective and safe treatment in patients with bacterial vaginosis (BV), candidal vulvovaginitis (CVV), and MVIs." 1 We agree that the score might be useful for management of vaginal infections.However, as a single arm trial, it cannot conclude whether it is effective than no therapy or not.Finally, the background degree of infection should be discussed.Success in management of vaginal infection is also associated with background severity, which can be access by vaginosis scoring. 2 A correlation to vaginosis score might give useful information on the efficacy of the drug.